您的位置: 首页 > 农业专利 > 详情页

ALLOGENEIC CAR-T PLATFORM USING HLA-MATCHED BANK OF IPSCS, AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS
专利权人:
Orig3n; Inc.
发明人:
Robin Y. Smith,Marcie A. Glicksman
申请号:
US16643814
公开号:
US20200206267A1
申请日:
2018.03.14
申请国别(地区):
US
年份:
2020
代理人:
摘要:
Presented herein are systems and methods of producing “universal” and/or “off-the-shelf” CAR-T compositions suitable for cancer therapy to be administered to one or more individuals. A CAR-T composition is a composition comprising one or more types of chimeric antigen receptor T cells (CAR-T). The iPSCs and/or cell lines, and any iPSC-derived CAR-T compositions derived therefrom, are identified as compatible with one or more individuals using an identification of a cell type indicative of compatibility (e.g., HLA match and/or ABO blood match and/or RHD blood match). The compatible cells are then retrieved from a managed HLA-indexed (and/or otherwise indexed) repository or are derived from a biological sample of a donor. The retrieved compatible cells are then used to derive iPSC-derived CAR-T compositions, wherein the derived compositions are suitable for therapy of one or more individuals.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充